



### **Indivior PLC – Director’s Change of Responsibilities**

**Slough, UK and Richmond, VA, 29 July, 2019** -- Indivior PLC announces that Frank Stier, Chief Manufacturing and Supply Officer, has informed the Company that he plans to retire in 2020. In light of this development, Mark Crossley, currently Chief Financial Officer, is appointed Chief Financial and Operations Officer. This change is effective immediately.

Commenting on the change, Shaun Thaxter, Chief Executive Officer said:

“Frank has shared his plan to retire, allowing for an appropriate and orderly transition of his duties. I would like to thank Frank for his loyal and dedicated service to Indivior. To help with an orderly transition and to best position the function, Frank will now report directly to Mark (as will Frank’s successor once appointed). This new organizational development acknowledges Mark’s strong performance and recognises the ongoing importance of Mark’s strategic contributions to the future of Indivior. As Mark currently oversees the finance and information technology functions, the addition of closely dependent functions, including manufacturing, supply, and procurement, creates even greater opportunities for improved collaboration and coordination across the departments.”

There have been no other changes to the information set out in LR 9.6.13R (2) to LR 9.6.13R (6) in respect of Mr Crossley.

This announcement is made in accordance with Listing Rule 9.6.14.

#### **About Indivior**

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is for all patients around the world to have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit [www.indivior.com](http://www.indivior.com) to learn more.

## **Forward-Looking Statements**

This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in such statements because they relate to future events. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance for 2019 and its medium- and long-term growth outlook, its operational goals, its product development pipeline and statements regarding ongoing litigation and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions.

Various factors may cause differences between Indivior's expectations and actual results, including, among others (including those described in the risk factors described in the most recent Indivior PLC Annual Report and in subsequent releases): factors affecting sales of Indivior Group's products and financial position; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group's drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved, if at all; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing and in the supply chain; disruptions in or failure of information technology systems; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; challenges in the commercial execution; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group's products and product candidates; risks related to legal proceedings, including the indictment by the U.S. Department of Justice, potential exclusion from participating in U.S. Federal Health Care Programs and the ongoing investigative and antitrust litigation matters; the Indivior Group's ability to protect its patents and other intellectual property; the outcome of patent infringement litigation relating to Indivior Group's products, including the ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.

Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.

## **Media Contacts**

Jonathan Sibun  
Tulchan Communications  
+44 207-353-4200

U.S. Media Inquiries  
[IndiviorMediaContacts@indivior.com](mailto:IndiviorMediaContacts@indivior.com)  
+1 804-594-0836

**Investor Contact**

Jason Thompson, Indivior  
Vice President, Investor Relations  
+1 804-423-8916  
[Jason.Thompson@indivior.com](mailto:Jason.Thompson@indivior.com)

© Indivior PLC | INDIVIOR is a registered trademark of Indivior UK Limited | All rights reserved

###